Država: Europska Unija
Jezik: engleski
Izvor: EMA (European Medicines Agency)
measles virus Enders’ Edmonston strain (live, attenuated), mumps virus Jeryl Lynn (level B) strain (live, attenuated), rubella virus Wistar RA 27/3 strain (live, attenuated)
Merck Sharp & Dohme B.V.
J07BD52
measles, mumps and rubella vaccine (live)
Vaccines
Rubella; Mumps; Immunization; Measles
M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older. For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.,
Revision: 30
Authorised
2006-05-05
34 B. PACKAG E LEAFLET 35 PACKAGE LEAFLET: INFORMATION FOR THE USER M-M-RVAXPRO POWDER AND SOLVENT FOR SUSPEN SION FOR INJECTION Measles, mumps and rub ella vaccine (live) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHIL D IS VACCINATED BECAUSE IT CONTAINS IMPORTANT IN FORMATION FOR YOU . - Keep this leaflet. You may need to read it again. - If you have any fur ther questions, ask your doc tor or your p harmacist. - If you get any of the side effects, talk to your doctor or pharmacist. This includes any pos sible side effects not l isted in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What M-M-RvaxPro is and what it is used for 2. What you need t o know before you receive M -M-RvaxPro 3. How to use M-M-RvaxPro 4. Possible sid e effects 5. How to store M-M-RvaxPro 6. Contents of the pack and other i nformation 1. WHAT M-M-RVAXPRO IS AND WHAT IT IS USED FOR M-M-RvaxPro is a vaccine co ntaining measle s, mumps and rubella viruses th at have been weakened. When a person is given t he vaccine, the immune sy stem (the body's natural defences ) will make antibodies against the measl es, mumps and rubella viruses. The an tibodi es help prot ect against infections caused by these viruses. M-M-RvaxPro is given to help protect yo u or your chil d a gainst measles, mumps and rubella. The vaccine m ay be admi nistered to persons 12 months of age or older. M-M-RvaxPro can be administ ere d to infants fro m 9 to 12 months of ag e under special circumstances. M-M-RvaxPro can also b e used in measles outbre aks, or for post-exposure vaccination, or for use in previously unvaccinated persons older than 9 months who are in contact with suscept ible pregnant women, and per sons likely t o be susceptible to mumps and ru bella. Although M-M-RvaxPro contains live viru ses , they are too weak to cause measles, mumps, or rubella in healthy people. 2. WHAT YOU NEED T O KNOW BEFORE YOU RECEIVE M -M-RVAXPRO DO NOT USE M-M-RVAXPRO - if t he person to be vaccinated is allergic to any measles, mumps or rube lla vaccine or Pročitajte cijeli dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for i nje ction in pre -filled syringe Measles, mumps and rubella vaccine (live) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Af ter reconstitution, one dose (0.5 mL) contains: Measles virus 1 Enders’ Edmonston strain (live, attenuated) ………..….not less than 1x10 3 TCID 50 * Mumps virus 1 Jer yl Lynn™ [Level B] strain (live, attenuated)……...…not less than 12.5x10 3 TCID 50 * Rubella virus 2 W istar RA 27/3 strain (live, attenuated) …………….….not less than 1x10 3 TCID 50 * *50% tissue culture infectious dose 1 produced in chick emb ryo cells. 2 produced in WI-38 human di ploid lung fibroblasts. The vaccine may contain traces of recombinant human albu min (rHA). This vaccine contains a trace amount of neomycin. See section 4.3. Excipient(s) with known effect The vaccine contains 14.5 milligrams of sorbitol per dose. See section 4.4. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and s olvent for suspension for injection. Before reconstitution, the powder is a light yellow compact crystalline cake a nd the solvent is a cl ear colourless liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS M-M-RvaxPro is indicated for simultaneou s vaccination against measles, mumps and rubella in individ uals from 12 months of age (see section 4.2). M-M-RvaxPro can be admini stered to infants f rom 9 months of age under special circumstances (see sections 4.2, 4.4 and 5.1). For use in measles outb r eaks, or for post - exposure vaccination, or, for use in prev iously unvaccinated individuals older than 9 months who are in contact with susceptible pr egnan t women, and persons likely to be susceptible to mumps and rubella, see section 5.1. M-M-RvaxPro is t o be used on the basis of official recommendations. 3 4.2 PO SOLOGY AND METHOD OF ADMINISTRATION Posology Individuals 12 months Pročitajte cijeli dokument